Baidu
map

Liquid Biopsy液体活检点名:CTC 循环肿瘤细胞 ,ctDNA 循环肿瘤DNA , Exosome 外泌体

2015-12-23 佚名 优迅医学

血液,你会想起什么?我们来看一下初中和高中课本里对血液是如何描述的: 掌握上述内容,估计是非专业人士对于血液成分了解的巅峰了,然而,就算是学霸,进了医院也是分分钟虐成渣。 因为医生眼里的血液是酱婶儿的: 或者这样婶儿 当然,这只是常规的入门项:全血和生化,还有很多专项检测可以招呼,想了解健康状况,你的血液可以把你出卖个底儿掉。不计成本的话,要不要来个全基因组的测序,你祖上哪

血液,你会想起什么?我们来看一下初中和高中课本里对血液是如何描述的:

掌握上述内容,估计是非专业人士对于血液成分了解的巅峰了,然而,就算是学霸,进了医院也是分分钟虐成渣。

因为医生眼里的血液是酱婶儿的:

或者这样婶儿

当然,这只是常规的入门项:全血和生化,还有很多专项检测可以招呼,想了解健康状况,你的血液可以把你出卖个底儿掉。不计成本的话,要不要来个全基因组的测序,你祖上哪里都能挖出来的呦~

在面对癌症这一棘手的敌人时,医生也有很多血清学标志物检测可供参考,但是这些标志物往往比较容易受影响,波动性很大,不具有很好的灵敏性和特异性。而近期大热的liquid biopsy不同于常规的标志物,它所检测的对象,是上述那些检测从未涉及的地方。这得益于科学研究的深入和测序技术的发展,使得我们对血液的了解也越来越深入,让我们从血液中能了解的信息也更多。

到底是血液里的什么让我们可以获取更多的信息,这些信息会对我们又有怎样的帮助呢?

CTC( 图片来源:Isolated, disseminated and circulating tumour cells in prostate cancer)

肿瘤细胞是一个疯狂的掠夺者,只在一地无法满足它的欲望。随着实体肿瘤的生长,在周围微环境发生了特定的变化时,就会促使一部分肿瘤细胞获得异常的活动能力(上皮间质转化,EMT)。这些细胞如同邪恶城堡派出的尖兵,从原发肿瘤上脱落,在身体里寻找新的落脚点。这些士兵会搭乘血液系统或淋巴系统去往身体各处,搭乘血液快线的脱落肿瘤细胞就被称为循环肿瘤细胞(CTC, Circulating Tumor Cells),在到达适宜的目标时他们又会变成恶性繁殖的机器(间质上皮转化,MET),建立新的邪恶堡垒。这就是肿瘤的血行转移,从原发部位形成继发性肿瘤。

然而想从血液中找到这些细胞谈何容易,每毫升血液里面CTC是论个数,而白细胞的数量级是106-107,红细胞的数量则更多(前面的检验单为证)。我们就拿白细胞与CTC计数做对比,健康人群的白细胞计数下限是每毫升4百万个,四大名着基本上每本都在100万字左右,粗略的计算一下:想从白细胞中找到CTC的感觉,和从四大名着中挑出一个错别字的感觉差不多。然而就算沉溺在血细胞的海洋里,我们也有办法让CTC也无所遁形。而科学家们的主要的工具就两样:筛子和吊钩。

正如上面的示意图所展示,CTC的大小和白细胞的大小有着细微的差别,因此我们可以用特定的筛子去筛选出体积较大的CTC。但是筛子的滤网只认体积,而细胞确是高矮胖瘦不齐:个子小的肿瘤细胞有可能漏下去,让我们误以为没有CTC细胞的检出,造成假阴性结果;个子大些的或者聚成团的白细胞,则可能无法穿过滤网,造成假阳性。

另一种方法,就是用吊钩。吊钩是根据CTC专门设计的,通过抗原抗体的识别功能,对CTC表面有而普通血细胞没有的抗原分子,进行特异性的吸附。基于这种原理,我们可以分离收集到绝大多数的CTC。大大提高了灵敏度和特异性。也有方法,将筛子和吊钩结合起来,以期更高效的获得CTC。

计数反映了肿瘤的转移情况,这很重要,因为影像学检测中的实体瘤的大小,与肿瘤的恶性程度和转移能力并不一定成正比,我们可以通过CTC计数及时监控。计数只是我们的第一步,这些脱落的细胞就是实体瘤的一部分,得到他们就相当于取得了实体瘤的组织,可以对肿瘤进行多种检测,以便了解病情,优化治疗方案。

目前,CTC的计数可用作于判断预后以及复发检测,而如果对CTC进一步分析,还可以指导肿瘤用药、掌握癌症的动态变化,检测抗性改变及时调整治疗方案。随着检测技术的升级,CTC在癌症诊疗过程中的价值,也越发被人们所重视,发表文献逐年增多(上图左),临床研究的数量覆盖的癌症种类也日趋扩大(上图右)。

ctDNA——蛛丝马迹

说道CTC,在液体活检中还有一个ct开头的,ctDNA(Circulating tumour DNA,循环肿瘤DNA)。ctDNA是cfDNA(cell-free DNA)的一种,是滴,就是课本血浆成分里的"其他",但是这个其他对于我们非常有价值,因为它是DNA,所以它是自带信息的物质,一般是来源于凋亡裂解的细胞。而肿瘤细胞破裂释放到血液中的游离DNA,就是ctDNA。

肿瘤细胞的基因组与正常细胞是不同的,会有一些肿瘤细胞特定的变异,因此我们可以通过阅读这些信息,了解肿瘤的情况。之前我们提到血液里面的肿瘤细胞分离都不容易,我们更没办法把这些DNA分离出来了。得益于测序成本的下降,和大规模平行测序技术的发展,我们不必在分子层面去分离ctDNA,而是通过测序,利用肿瘤细胞基因组的特点,从携带信息的层面去挑出属于肿瘤细胞的部分。

由于ctDNA的浓度与肿瘤的进展高度相关,因此我们可以通过ctDNA来进行肿瘤的分期、预后评估,以及动态监测。它携带的肿瘤信息也可用于用药指导,不光取样简单,还能更全面的掌握肿瘤的信息。之所以这样说是因为肿瘤细胞的基因组不稳定,在细胞分裂的过程中,会不断产生变异,手术取得的组织样本,就好像是抽样,其结果并不代表全部的肿瘤细胞。而ctDNA可来自于任何裂解的肿瘤细胞,更能反映出肿瘤细胞整体的基因变异信息。

cfDNA中还有一类大家应该不太陌生,cffDNA(cell-free fetus DNA),是母亲血液中的胎儿游离DNA,主要来源于胎盘细胞。它虽然含量很少,但是借助高通量测序技术以及生物信息统计分析对21-三体、18三体、13三体三种染色体非整倍性疾病的检测准确性已经非常之高,远高于主要通过血清学指标的传统唐氏筛查

Exosome——特战小分队

除了CTC和ct-DNA,在液体活检这个exosome(外泌体)可是液体活检的新贵呢!

外泌体是细胞分泌出的小泡,这个小泡泡包含的内容非常多,有蛋白质、DNA、信使RNA以及一些非编码RNA,是细胞之间沟通的载体。研究发现肿瘤细胞释放的外泌体的量较大,这些外泌体与肿瘤的发生、发展、转移以及抗药性具有一定的相关性。肿瘤细胞以这些邪恶的小泡为载体,迷惑免疫系统,帮助肿瘤细胞逃过免疫系统的监视。这些小泡不光当通讯兵,也是工兵连,给肿瘤细胞的转移指引方向的同时,也创造适合肿瘤生长的微环境。

外泌体携带的信息多样化,其中的蛋白质和核酸,均可用于癌症的早诊、复发监测、抗药性监测等相关方面的分析。而且外泌体在数量上多于CTC,更易富集;在形式上分泌小泡能够有效保护核酸类物质,克服了ctDNA在血液中容易降解的问题,在临床应用上大有可为。[4]

Liquid Biopsy液体活检

三个检测物:

CTC 循环肿瘤细胞 / ctDNA 循环肿瘤DNA / Exosome 外泌体

主要优点:

克服肿瘤异质性、无创取样、实时分析

重要功能:

癌症早诊、辅助分期、预后评估、复发监测、用药指导

原文标题:Liquid Biopsy液体活检:周晔博士在博鳌健康论坛的报告里都说了什么?

(生物谷 Bioon.com)

相关会议推荐:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1895560, encodeId=c84e189556081, content=<a href='/topic/show?id=428c5388a9' target=_blank style='color:#2F92EE;'>#CTC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5388, encryptionId=428c5388a9, topicName=CTC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Tue Dec 29 19:22:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707516, encodeId=8fe81e07516e2, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Fri Apr 29 02:22:00 CST 2016, time=2016-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785915, encodeId=a7d41e8591567, content=<a href='/topic/show?id=52d5e16003' target=_blank style='color:#2F92EE;'>#Exosome#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7160, encryptionId=52d5e16003, topicName=Exosome)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=734374, createdName=gjsgj, createdTime=Wed Feb 17 17:22:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52710, encodeId=df0a52e10e9, content=新的东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Thu Jan 07 11:28:00 CST 2016, time=2016-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917235, encodeId=78d8191e2351f, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jan 11 17:22:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48130, encodeId=b1a748130be, content=新, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 15:21:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47838, encodeId=30f04e8389a, content=很有应用前景。, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Sat Dec 26 01:02:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47639, encodeId=adb94e63991, content=赞,什么时候能在临床开张, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Fri Dec 25 07:01:00 CST 2015, time=2015-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277961, encodeId=1eda12e79611e, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri Dec 25 00:22:00 CST 2015, time=2015-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312924, encodeId=1b50131292404, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Fri Dec 25 00:22:00 CST 2015, time=2015-12-25, status=1, ipAttribution=)]
    2015-12-29 kalseyzl
  2. [GetPortalCommentsPageByObjectIdResponse(id=1895560, encodeId=c84e189556081, content=<a href='/topic/show?id=428c5388a9' target=_blank style='color:#2F92EE;'>#CTC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5388, encryptionId=428c5388a9, topicName=CTC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Tue Dec 29 19:22:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707516, encodeId=8fe81e07516e2, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Fri Apr 29 02:22:00 CST 2016, time=2016-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785915, encodeId=a7d41e8591567, content=<a href='/topic/show?id=52d5e16003' target=_blank style='color:#2F92EE;'>#Exosome#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7160, encryptionId=52d5e16003, topicName=Exosome)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=734374, createdName=gjsgj, createdTime=Wed Feb 17 17:22:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52710, encodeId=df0a52e10e9, content=新的东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Thu Jan 07 11:28:00 CST 2016, time=2016-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917235, encodeId=78d8191e2351f, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jan 11 17:22:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48130, encodeId=b1a748130be, content=新, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 15:21:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47838, encodeId=30f04e8389a, content=很有应用前景。, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Sat Dec 26 01:02:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47639, encodeId=adb94e63991, content=赞,什么时候能在临床开张, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Fri Dec 25 07:01:00 CST 2015, time=2015-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277961, encodeId=1eda12e79611e, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri Dec 25 00:22:00 CST 2015, time=2015-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312924, encodeId=1b50131292404, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Fri Dec 25 00:22:00 CST 2015, time=2015-12-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1895560, encodeId=c84e189556081, content=<a href='/topic/show?id=428c5388a9' target=_blank style='color:#2F92EE;'>#CTC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5388, encryptionId=428c5388a9, topicName=CTC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Tue Dec 29 19:22:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707516, encodeId=8fe81e07516e2, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Fri Apr 29 02:22:00 CST 2016, time=2016-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785915, encodeId=a7d41e8591567, content=<a href='/topic/show?id=52d5e16003' target=_blank style='color:#2F92EE;'>#Exosome#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7160, encryptionId=52d5e16003, topicName=Exosome)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=734374, createdName=gjsgj, createdTime=Wed Feb 17 17:22:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52710, encodeId=df0a52e10e9, content=新的东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Thu Jan 07 11:28:00 CST 2016, time=2016-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917235, encodeId=78d8191e2351f, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jan 11 17:22:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48130, encodeId=b1a748130be, content=新, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 15:21:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47838, encodeId=30f04e8389a, content=很有应用前景。, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Sat Dec 26 01:02:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47639, encodeId=adb94e63991, content=赞,什么时候能在临床开张, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Fri Dec 25 07:01:00 CST 2015, time=2015-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277961, encodeId=1eda12e79611e, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri Dec 25 00:22:00 CST 2015, time=2015-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312924, encodeId=1b50131292404, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Fri Dec 25 00:22:00 CST 2015, time=2015-12-25, status=1, ipAttribution=)]
    2016-02-17 gjsgj
  4. [GetPortalCommentsPageByObjectIdResponse(id=1895560, encodeId=c84e189556081, content=<a href='/topic/show?id=428c5388a9' target=_blank style='color:#2F92EE;'>#CTC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5388, encryptionId=428c5388a9, topicName=CTC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Tue Dec 29 19:22:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707516, encodeId=8fe81e07516e2, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Fri Apr 29 02:22:00 CST 2016, time=2016-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785915, encodeId=a7d41e8591567, content=<a href='/topic/show?id=52d5e16003' target=_blank style='color:#2F92EE;'>#Exosome#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7160, encryptionId=52d5e16003, topicName=Exosome)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=734374, createdName=gjsgj, createdTime=Wed Feb 17 17:22:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52710, encodeId=df0a52e10e9, content=新的东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Thu Jan 07 11:28:00 CST 2016, time=2016-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917235, encodeId=78d8191e2351f, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jan 11 17:22:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48130, encodeId=b1a748130be, content=新, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 15:21:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47838, encodeId=30f04e8389a, content=很有应用前景。, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Sat Dec 26 01:02:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47639, encodeId=adb94e63991, content=赞,什么时候能在临床开张, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Fri Dec 25 07:01:00 CST 2015, time=2015-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277961, encodeId=1eda12e79611e, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri Dec 25 00:22:00 CST 2015, time=2015-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312924, encodeId=1b50131292404, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Fri Dec 25 00:22:00 CST 2015, time=2015-12-25, status=1, ipAttribution=)]
    2016-01-07 huangwukui

    新的东西

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1895560, encodeId=c84e189556081, content=<a href='/topic/show?id=428c5388a9' target=_blank style='color:#2F92EE;'>#CTC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5388, encryptionId=428c5388a9, topicName=CTC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Tue Dec 29 19:22:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707516, encodeId=8fe81e07516e2, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Fri Apr 29 02:22:00 CST 2016, time=2016-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785915, encodeId=a7d41e8591567, content=<a href='/topic/show?id=52d5e16003' target=_blank style='color:#2F92EE;'>#Exosome#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7160, encryptionId=52d5e16003, topicName=Exosome)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=734374, createdName=gjsgj, createdTime=Wed Feb 17 17:22:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52710, encodeId=df0a52e10e9, content=新的东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Thu Jan 07 11:28:00 CST 2016, time=2016-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917235, encodeId=78d8191e2351f, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jan 11 17:22:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48130, encodeId=b1a748130be, content=新, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 15:21:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47838, encodeId=30f04e8389a, content=很有应用前景。, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Sat Dec 26 01:02:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47639, encodeId=adb94e63991, content=赞,什么时候能在临床开张, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Fri Dec 25 07:01:00 CST 2015, time=2015-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277961, encodeId=1eda12e79611e, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri Dec 25 00:22:00 CST 2015, time=2015-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312924, encodeId=1b50131292404, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Fri Dec 25 00:22:00 CST 2015, time=2015-12-25, status=1, ipAttribution=)]
    2016-01-11 sunylz
  6. [GetPortalCommentsPageByObjectIdResponse(id=1895560, encodeId=c84e189556081, content=<a href='/topic/show?id=428c5388a9' target=_blank style='color:#2F92EE;'>#CTC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5388, encryptionId=428c5388a9, topicName=CTC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Tue Dec 29 19:22:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707516, encodeId=8fe81e07516e2, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Fri Apr 29 02:22:00 CST 2016, time=2016-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785915, encodeId=a7d41e8591567, content=<a href='/topic/show?id=52d5e16003' target=_blank style='color:#2F92EE;'>#Exosome#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7160, encryptionId=52d5e16003, topicName=Exosome)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=734374, createdName=gjsgj, createdTime=Wed Feb 17 17:22:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52710, encodeId=df0a52e10e9, content=新的东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Thu Jan 07 11:28:00 CST 2016, time=2016-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917235, encodeId=78d8191e2351f, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jan 11 17:22:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48130, encodeId=b1a748130be, content=新, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 15:21:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47838, encodeId=30f04e8389a, content=很有应用前景。, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Sat Dec 26 01:02:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47639, encodeId=adb94e63991, content=赞,什么时候能在临床开张, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Fri Dec 25 07:01:00 CST 2015, time=2015-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277961, encodeId=1eda12e79611e, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri Dec 25 00:22:00 CST 2015, time=2015-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312924, encodeId=1b50131292404, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Fri Dec 25 00:22:00 CST 2015, time=2015-12-25, status=1, ipAttribution=)]
    2015-12-26 hixiaoluo

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1895560, encodeId=c84e189556081, content=<a href='/topic/show?id=428c5388a9' target=_blank style='color:#2F92EE;'>#CTC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5388, encryptionId=428c5388a9, topicName=CTC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Tue Dec 29 19:22:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707516, encodeId=8fe81e07516e2, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Fri Apr 29 02:22:00 CST 2016, time=2016-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785915, encodeId=a7d41e8591567, content=<a href='/topic/show?id=52d5e16003' target=_blank style='color:#2F92EE;'>#Exosome#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7160, encryptionId=52d5e16003, topicName=Exosome)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=734374, createdName=gjsgj, createdTime=Wed Feb 17 17:22:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52710, encodeId=df0a52e10e9, content=新的东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Thu Jan 07 11:28:00 CST 2016, time=2016-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917235, encodeId=78d8191e2351f, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jan 11 17:22:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48130, encodeId=b1a748130be, content=新, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 15:21:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47838, encodeId=30f04e8389a, content=很有应用前景。, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Sat Dec 26 01:02:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47639, encodeId=adb94e63991, content=赞,什么时候能在临床开张, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Fri Dec 25 07:01:00 CST 2015, time=2015-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277961, encodeId=1eda12e79611e, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri Dec 25 00:22:00 CST 2015, time=2015-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312924, encodeId=1b50131292404, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Fri Dec 25 00:22:00 CST 2015, time=2015-12-25, status=1, ipAttribution=)]
    2015-12-26 jetleo

    很有应用前景。

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1895560, encodeId=c84e189556081, content=<a href='/topic/show?id=428c5388a9' target=_blank style='color:#2F92EE;'>#CTC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5388, encryptionId=428c5388a9, topicName=CTC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Tue Dec 29 19:22:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707516, encodeId=8fe81e07516e2, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Fri Apr 29 02:22:00 CST 2016, time=2016-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785915, encodeId=a7d41e8591567, content=<a href='/topic/show?id=52d5e16003' target=_blank style='color:#2F92EE;'>#Exosome#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7160, encryptionId=52d5e16003, topicName=Exosome)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=734374, createdName=gjsgj, createdTime=Wed Feb 17 17:22:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52710, encodeId=df0a52e10e9, content=新的东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Thu Jan 07 11:28:00 CST 2016, time=2016-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917235, encodeId=78d8191e2351f, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jan 11 17:22:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48130, encodeId=b1a748130be, content=新, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 15:21:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47838, encodeId=30f04e8389a, content=很有应用前景。, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Sat Dec 26 01:02:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47639, encodeId=adb94e63991, content=赞,什么时候能在临床开张, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Fri Dec 25 07:01:00 CST 2015, time=2015-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277961, encodeId=1eda12e79611e, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri Dec 25 00:22:00 CST 2015, time=2015-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312924, encodeId=1b50131292404, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Fri Dec 25 00:22:00 CST 2015, time=2015-12-25, status=1, ipAttribution=)]
    2015-12-25 wzf990214

    赞,什么时候能在临床开张

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1895560, encodeId=c84e189556081, content=<a href='/topic/show?id=428c5388a9' target=_blank style='color:#2F92EE;'>#CTC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5388, encryptionId=428c5388a9, topicName=CTC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Tue Dec 29 19:22:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707516, encodeId=8fe81e07516e2, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Fri Apr 29 02:22:00 CST 2016, time=2016-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785915, encodeId=a7d41e8591567, content=<a href='/topic/show?id=52d5e16003' target=_blank style='color:#2F92EE;'>#Exosome#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7160, encryptionId=52d5e16003, topicName=Exosome)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=734374, createdName=gjsgj, createdTime=Wed Feb 17 17:22:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52710, encodeId=df0a52e10e9, content=新的东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Thu Jan 07 11:28:00 CST 2016, time=2016-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917235, encodeId=78d8191e2351f, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jan 11 17:22:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48130, encodeId=b1a748130be, content=新, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 15:21:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47838, encodeId=30f04e8389a, content=很有应用前景。, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Sat Dec 26 01:02:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47639, encodeId=adb94e63991, content=赞,什么时候能在临床开张, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Fri Dec 25 07:01:00 CST 2015, time=2015-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277961, encodeId=1eda12e79611e, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri Dec 25 00:22:00 CST 2015, time=2015-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312924, encodeId=1b50131292404, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Fri Dec 25 00:22:00 CST 2015, time=2015-12-25, status=1, ipAttribution=)]
    2015-12-25 smlt2008
  10. [GetPortalCommentsPageByObjectIdResponse(id=1895560, encodeId=c84e189556081, content=<a href='/topic/show?id=428c5388a9' target=_blank style='color:#2F92EE;'>#CTC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5388, encryptionId=428c5388a9, topicName=CTC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c77e138, createdName=kalseyzl, createdTime=Tue Dec 29 19:22:00 CST 2015, time=2015-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1707516, encodeId=8fe81e07516e2, content=<a href='/topic/show?id=9f7c99e256' target=_blank style='color:#2F92EE;'>#IOP#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9972, encryptionId=9f7c99e256, topicName=IOP)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6bb031431834, createdName=124987c6m46暂无昵称, createdTime=Fri Apr 29 02:22:00 CST 2016, time=2016-04-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1785915, encodeId=a7d41e8591567, content=<a href='/topic/show?id=52d5e16003' target=_blank style='color:#2F92EE;'>#Exosome#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7160, encryptionId=52d5e16003, topicName=Exosome)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=734374, createdName=gjsgj, createdTime=Wed Feb 17 17:22:00 CST 2016, time=2016-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=52710, encodeId=df0a52e10e9, content=新的东西, beContent=null, objectType=article, channel=null, level=null, likeNumber=157, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=90ea1614944, createdName=huangwukui, createdTime=Thu Jan 07 11:28:00 CST 2016, time=2016-01-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1917235, encodeId=78d8191e2351f, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon Jan 11 17:22:00 CST 2016, time=2016-01-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=48130, encodeId=b1a748130be, content=新, beContent=null, objectType=article, channel=null, level=null, likeNumber=130, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=bc301610909, createdName=hixiaoluo, createdTime=Sat Dec 26 15:21:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47838, encodeId=30f04e8389a, content=很有应用前景。, beContent=null, objectType=article, channel=null, level=null, likeNumber=119, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4bfa83595, createdName=jetleo, createdTime=Sat Dec 26 01:02:00 CST 2015, time=2015-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=47639, encodeId=adb94e63991, content=赞,什么时候能在临床开张, beContent=null, objectType=article, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mStl88fu4NfNLvzZhgPxRiaKicWybj5Q5KN7PWibALciaJ4W5bZwTlDSFRibFu87125pCq0IXePrC0mpbiasADRqL4NcjUoyQCT9De/0, createdBy=7c7e1636498, createdName=wzf990214, createdTime=Fri Dec 25 07:01:00 CST 2015, time=2015-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1277961, encodeId=1eda12e79611e, content=<a href='/topic/show?id=d34e6523544' target=_blank style='color:#2F92EE;'>#活检#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=65235, encryptionId=d34e6523544, topicName=活检)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c39f145, createdName=smlt2008, createdTime=Fri Dec 25 00:22:00 CST 2015, time=2015-12-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312924, encodeId=1b50131292404, content=<a href='/topic/show?id=4ce783062c7' target=_blank style='color:#2F92EE;'>#肿瘤细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=57, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83062, encryptionId=4ce783062c7, topicName=肿瘤细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c859411, createdName=hmwwww, createdTime=Fri Dec 25 00:22:00 CST 2015, time=2015-12-25, status=1, ipAttribution=)]

相关资讯

肿瘤液体活检技术:CTC和ctDNA孰优孰劣?

如果医生想深入了解肿瘤,他们的选择很有限。他们可以扫描相关区域、采集组织活检,或监控血液的标志物,如PSA或CA 125。不过,这些都不太理想:成像的分辨率不高,活检是侵入性的,而良好的标志物是少之又少。最理想的情况是,研究人员能通过简单的血液检测来实现组织活检的敏感性和特异性。如今,液体活检的出现,让这一切成为可能。液体活检据斯坦福大学医学院的助理教授Max Diehn介绍,就传统的癌症标志

可能改变癌症治疗的新方法:液体活检

在美国,一种新的血液检测方法正开始改变癌症治疗,为一些病人省去了手术活检和穿刺活检,这两种活检是长期需要来指导病人癌症治疗的。 这种被称为液体活检的检测方法,可以捕获到肿瘤脱落进入血液的肿瘤细胞或DNA,从而替代了从肿瘤本身提取组织。关于这些检测方法的价值,现在还有很多不清楚的地方,但是许多医生认为,这些检测方法是一个很大的进步,可能可以为更多的病人实现个体化治疗。 这些检测方法是第一

液体活检技术临床应用进展:CTC,ctDNA和外泌体检测

液体活检(Liquid biopsy)的检测方法,可以捕获到进入血液的其它细胞或DNA,从而替代了疾病的诊断,例如肿瘤。关于这些检测方法的价值,现在还有很多不清楚的地方,但是许多医生认为,这些检测方法是一个很大的进步,可能可以为更多的病人实现个体化治疗。 这些检测方法是第一次非介入性地,可重复性地抽取肿瘤样本,医生们从而可以建立基因表达谱,靶向突变用药,快速判断治疗是否有效,及随肿瘤的发

2015长城会:液体活检,预测心源性猝死新方法

第二十六届长城国际心脏病学会议 第九届北京五洲国际心血管病会议2015 亚太心脏大会暨国际心血管病预防与康复会议2015    Samuel Dudley教授 近年来心血管事件后患者生存率显著提高,以致心衰和心源性猝死发生率居高不下,令人担忧。尽管临床试验肯定了置入式心脏复律除颤器(ICD)对预防心源性猝死的益处,但具体到ICD资源合理分配仍存在

Baidu
map
Baidu
map
Baidu
map